Thrombosis News and Research

Latest Thrombosis News and Research

IPMT procedure can benefit patients with acute deep vein thrombosis

Patients with acute deep vein thrombosis (DVT) develop potentially dangerous blood clots and can suffer severe leg pain and swelling. Doctors with Virginia Interventional & Vascular Associates (VIVA) report success over the past two years in treating acute DVT patients with a procedure called isolated pharmacomechanical thrombolysis (IPMT), which destroys clots much faster than traditional therapies.

7 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).

5 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

BioInvent International AB announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.

4 Jan 2010

Eritoran well tolerated in Phase II trial for severe sepsis

The investigational compound, eritoran tetrasodium ("eritoran," also known as E5564) appeared to be well tolerated in patients with severe sepsis in a Phase II trial published in the January issue of Critical Care Medicine, the official journal of the Society of Critical Care Medicine, the largest multiprofessional organization dedicated to ensuring excellence and consistency in the practice of critical care.

22 Dec 2009

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

ZymoGenetics, Inc. today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM® Thrombin, topical (Recombinant).

21 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Regado Biosciences announces completion of Series D financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.

18 Dec 2009

Maine-based EMHS recognized for creating system-wide culture of safety

A poor economy in a rural area might seem like overwhelming obstacles to creating a sophisticated culture of safety in a health care system that serves the largest aging population in the country, but leaders at Eastern Maine Healthcare Systems (EMHS) beat those odds in 2009.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

Latest findings on how blood clots form can open door to the development of new drugs

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Experts call on Europe's policy makers to take urgent action against preventable strokes

A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year

9 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Thrombosis News and Research

Latest Thrombosis News and Research

IPMT procedure can benefit patients with acute deep vein thrombosis

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

Eritoran well tolerated in Phase II trial for severe sepsis

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Regado Biosciences announces completion of Series D financing

Maine-based EMHS recognized for creating system-wide culture of safety

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Special issue focuses on cardiovascular disease prevention and outcomes

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Latest findings on how blood clots form can open door to the development of new drugs

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Experts call on Europe's policy makers to take urgent action against preventable strokes

New guidelines on the management of antithrombotic agents for endoscopic procedures published

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thrombosis News and Research

Latest Thrombosis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in